OCA IR 0.1 mg, 0,1 mg and 1,5 mg Placebo tablets, OCA 1.5 mg clinical trials

A Randomized, Double-blind, Placebo-controlled, Phase 2/3 Study to Assess the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Obeticholic Acid Compared to Placebo in Pediatric Subjects with Biliary Atresia, Post-hepatoportoenterostomy

This study is testing a new medicine, obeticholic acid (OCA), for children and young adults with biliary atresia who have had a specific surgery. We want to see if OCA can help slow down liver disease and improve their health.